Funding for this research was provided by:
Cancer Research UK (C60100/A23916)
Dr. Josef Steiner Krebsstiftung
Medical Research Council (Grant-in-Aid MRC Cancer Unit)
Wellcome Trust (4-year PhD Studentship (Sanger Institute))
Article History
Received: 11 November 2019
Accepted: 30 January 2020
First Online: 14 February 2020
Competing interests
: SNZ holds patents on clinical algorithms of mutational signatures and, during the completion of this manuscript, served advisory roles for Astra Zeneca, Artios Pharma Ltd, and Scottish Genome Project. The other authors declare that they have no competing interests.